RAAS inhibition in COVID-19 Patients
PMID: 32526012 DOI: 10.1093/infdis/jiaa332
Shyh et al. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe? Cardiol Rev. Jul/Aug 2020;28(4):213-216.
PMID: 32496364 DOI: 10.1097/CRD.0000000000000319
Amat et al. Ramipril in High Risk Patients With COVID-19. J Am Coll Cardiol. 2020 May 22;S0735-1097(20)35395-X.
PMID: 32470515 PMCID: PMC7250557 DOI: 10.1016/j.jacc.2020.05.040
Aleksova et al. COVID-19 and Renin-Angiotensin System Inhibition: Role of Angiotensin Converting Enzyme 2 (ACE2) – Is There Any Scientific Evidence for Controversy? J Intern Med 2020 May 27;
PMID: 32459372 PMCID: PMC7283873 DOI: 10.1111/joim.13101
Daniel et al. ACE-inhibitors and Angiotensin-2 Receptor Blockers Are Not Associated With Severe SARS-COVID19 Infection in a Multi-Site UK Acute Hospital Trust. Eur J Heart Fail. 2020 Jun 2.
PMID: 32485082 DOI: 10.1002/ejhf.1924
Kewen Qian et al. Ig-like ACE2 Protein Therapeutics: A Revival in Development During the COVID-19 Pandemic. MAbs. 2020 Jun 16;1782600.
PMID: 32546047 DOI: 10.1080/19420862.2020.1782600
Seyed-Mohammad et al. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking Out of Our Sight? Iran J Allergy Asthma Immunol. 2020 May 17;19(S1):13-17.doi: 10.18502/ijaai.v19i(s1.r1).2850.
Matthew J Camiolo et al. Expression of SARS-CoV-2 Receptor ACE2 and Coincident Host Response Signature Varies by Asthma Inflammatory Phenotype. J Allergy Clin Immunol. 2020 Jun 9;S0091-6749(20)30828-9.
PMID: 32531372 PMCID: PMC7283064 DOI: 10.1016/j.jaci.2020.05.051
A H. Jan Danser et al. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension. 2020 Jun;75(6):1382-1385.
PMID: 32208987 PMCID: PMC7225046 DOI: 10.1161/HYPERTENSIONAHA.120.15082
Abhinav Grover et al. A Systematic Review and Meta-Analysis to Evaluate the Clinical Outcomes in COVID-19 Patients on Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. Eur Heart J Cardiovasc Pharmacother. 2020 Jun 15;pvaa064.
PMID: 32542337 DOI: 10.1093/ehjcvp/pvaa064
Sophie Liabeuf et al. Association Between Renin-Angiotensin System Inhibitors and COVID-19 Complications. Eur Heart J Cardiovasc Pharmacother. 2020 Jun 12;pvaa062.
PMID: 32531040 DOI: 10.1093/ehjcvp/pvaa062
Valente Maldonado et al. Repositioning of Pentoxifylline as an Immunomodulator and Regulator of the Renin-Angiotensin System in the Treatment of COVID-19. Med Hypotheses. 2020 Jun 9;144:109988.
PMID: 32540603 PMCID: PMC7282759 DOI: 10.1016/j.mehy.2020.109988
A A A F de Vries. Renin-angiotensin System Inhibition in COVID-19 Patients. Neth Heart J. 2020 Jun 8;1-6.
PMID: 32514935 PMCID: PMC7278773 DOI: 10.1007/s12471-020-01439-5
C Felice et al. Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives. Am J Hypertens. 2020 Jun 8;hpaa096.
PMID: 32511678 DOI: 10.1093/ajh/hpaa096
Fosbol et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA. 2020 Jun 19;e2011301.
PMID: 32558877 PMCID: PMC7305566 (available on 2020-12-19) DOI: 10.1001/jama.2020.11301
Grover et al. A Systematic Review and Meta-Analysis to Evaluate the Clinical Outcomes in COVID-19 Patients on Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. Eur Heart J Cardiovasc Pharmacother. 2020 Jun 15;pvaa 064.
PMID: 32542337 DOI: 10.1093/ehjcvp/pvaa064
Khashkhusha et al. ACEi and ARB With COVID-19. J Card Surg. 2020 Jun;35(6):1388. PMID: 32531123 DOI: 10.1111/jocs.14649
Hu et al. COVID-19 Patients With Hypertension Have More Severity Condition, and ACEI/ARB Treatment Have No Infulence on the Clinical Severity and Outcome. J Infect. 2020 May 28;S0163-4453(20)30334-0.
PMID: 32474032 PMCID: PMC7255723 DOI: 10.1016/j.jinf.2020.05.056
Kai et al. Interactions of Coronaviruses With ACE2, Angiotensin II, and RAS Inhibitors-Lessons From Available Evidence and Insights Into COVID-19. Hypertens Res. 2020 Jul;43(7):648-654.
PMID: 32341442 PMCID: PMC7184165 DOI: 10.1038/s41440-020-0455-8
Selçuk et al. Is the Use of ACE inb/ARBs Associated With Higher In-Hospital Mortality in Covid-19 Pneumonia Patients? Clin Exp Hypertens. 2020 Jun 22; 1-5.
PMID: 32569491 DOI: 10.1080/10641963.2020.1783549
Arnold et al. COVID-19 – Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack? Heart Lung Circ. 2020 May 25;S1443-9506(20)30145-1.
PMID: 32564908 DOI: 10.1016/j.hlc.2020.05.004
Laccardino et al. Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. Hypertension. 2020 Jun 22;
PMID: 32564693 DOI: 10.1161/HYPERTENSIONAHA.120.15324
Emilsson et al. Antihypertensive Medication Uses and Serum ACE2 Levels: ACEIs/ARBs Treatment Does Not Raise Serum Levels of ACE2. medRxiv. 2020 May 25;2020.05.21.20108738.
PMID: 32511473 PMCID: PMC7265694 DOI: 10.1101/2020.05.21.20108738
Infusino et al. Relationship Between ACE-inhibitors, ARBs and SARS-CoV-2 Infection: Where Are We? Minerva Cardioangiol. 2020 May 29
PMID: 32472989 DOI: 10.23736/S0026-4725.20.05271-8
Gommans et al. Rationale and Design of the PRAETORIAN-COVID Trial: A Double-Blind, Placebo-Controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 Infection Disease. Am Heart J. 2020 May 21;226:60-68
PMID: 32512291 PMCID: PMC7239793 DOI: 10.1016/j.ahj.2020.05.010
Liu et al. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management. J Transl Int Med. 2020 May 9;8(1):9-19.
PMID: 32435607 PMCID: PMC7227161 DOI: 10.2478/jtim-2020-0003
Alexandre et al. Drugs Acting on Renin Angiotensin System and Use in Ill Patients With COVID-19. Therapie. 2020 May 20;S0040-5957(20)30099-8.
PMID: 32553503 PMCID: PMC7238972 DOI: 10.1016/j.therap.2020.05.009
